CO2022003062A2 - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- CO2022003062A2 CO2022003062A2 CONC2022/0003062A CO2022003062A CO2022003062A2 CO 2022003062 A2 CO2022003062 A2 CO 2022003062A2 CO 2022003062 A CO2022003062 A CO 2022003062A CO 2022003062 A2 CO2022003062 A2 CO 2022003062A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- heterocyclic compounds
- methods
- indicated
- making
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (I) en donde A, L, Q, U, V, W, X, Z, m, n y R1 a R4 son tal como se indica en la presente, en donde las composiciones incluyen los compuestos, procedimientos de fabricación de los compuestos y métodos de uso de los compuestos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19198974 | 2019-09-23 | ||
CN2020109184 | 2020-08-14 | ||
PCT/EP2020/076228 WO2021058416A1 (en) | 2019-09-23 | 2020-09-21 | Heterocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022003062A2 true CO2022003062A2 (es) | 2022-04-19 |
Family
ID=72659185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0003062A CO2022003062A2 (es) | 2019-09-23 | 2022-03-17 | Compuestos heterocíclicos |
Country Status (15)
Country | Link |
---|---|
US (2) | US20210107921A1 (es) |
EP (1) | EP4034239A1 (es) |
JP (1) | JP2022549810A (es) |
KR (1) | KR20220066894A (es) |
CN (1) | CN114401969A (es) |
AU (1) | AU2020355507A1 (es) |
BR (1) | BR112022003982A2 (es) |
CA (1) | CA3155161A1 (es) |
CO (1) | CO2022003062A2 (es) |
CR (1) | CR20220116A (es) |
IL (1) | IL289617A (es) |
MX (1) | MX2022003023A (es) |
PE (1) | PE20221450A1 (es) |
TW (1) | TW202120502A (es) |
WO (1) | WO2021058416A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
WO2019105915A1 (en) | 2017-11-28 | 2019-06-06 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
TW201938164A (zh) | 2018-01-08 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎雜環化合物 |
PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
BR112022002375A2 (pt) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
MX2023002224A (es) | 2020-09-03 | 2023-03-15 | Hoffmann La Roche | Compuestos heterociclicos. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
WO2012155199A1 (en) | 2011-05-16 | 2012-11-22 | Bionomics Limited | Amine derivatives as potassium channel blockers |
WO2016158956A1 (ja) * | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | 複素環化合物 |
JP2018515612A (ja) | 2015-05-13 | 2018-06-14 | セルビタ スプウカ アクツィーナ | 置換キノキサリン誘導体 |
WO2019105915A1 (en) * | 2017-11-28 | 2019-06-06 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
TW201930300A (zh) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
TW201938164A (zh) * | 2018-01-08 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎雜環化合物 |
SI3768684T1 (sl) * | 2018-03-22 | 2023-06-30 | F. Hoffmann - La Roche Ag | Zaviralci oksazin monoacilglicerol lipaze (MAGL) |
PE20211380A1 (es) * | 2018-08-13 | 2021-07-27 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa |
PE20211089A1 (es) * | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
-
2020
- 2020-09-21 JP JP2022518270A patent/JP2022549810A/ja active Pending
- 2020-09-21 PE PE2022000376A patent/PE20221450A1/es unknown
- 2020-09-21 MX MX2022003023A patent/MX2022003023A/es unknown
- 2020-09-21 CN CN202080063282.3A patent/CN114401969A/zh active Pending
- 2020-09-21 BR BR112022003982A patent/BR112022003982A2/pt not_active Application Discontinuation
- 2020-09-21 AU AU2020355507A patent/AU2020355507A1/en active Pending
- 2020-09-21 EP EP20780603.5A patent/EP4034239A1/en active Pending
- 2020-09-21 WO PCT/EP2020/076228 patent/WO2021058416A1/en unknown
- 2020-09-21 CR CR20220116A patent/CR20220116A/es unknown
- 2020-09-21 KR KR1020227009405A patent/KR20220066894A/ko unknown
- 2020-09-21 CA CA3155161A patent/CA3155161A1/en active Pending
- 2020-09-21 US US17/026,619 patent/US20210107921A1/en not_active Abandoned
- 2020-09-22 TW TW109132688A patent/TW202120502A/zh unknown
-
2022
- 2022-01-04 IL IL289617A patent/IL289617A/en unknown
- 2022-01-31 US US17/588,816 patent/US20220267349A1/en not_active Abandoned
- 2022-03-17 CO CONC2022/0003062A patent/CO2022003062A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022549810A (ja) | 2022-11-29 |
EP4034239A1 (en) | 2022-08-03 |
MX2022003023A (es) | 2022-04-07 |
US20210107921A1 (en) | 2021-04-15 |
TW202120502A (zh) | 2021-06-01 |
BR112022003982A2 (pt) | 2022-05-24 |
CA3155161A1 (en) | 2021-04-01 |
IL289617A (en) | 2022-03-01 |
CN114401969A (zh) | 2022-04-26 |
US20220267349A1 (en) | 2022-08-25 |
KR20220066894A (ko) | 2022-05-24 |
PE20221450A1 (es) | 2022-09-21 |
WO2021058416A1 (en) | 2021-04-01 |
CR20220116A (es) | 2022-04-20 |
AU2020355507A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022003062A2 (es) | Compuestos heterocíclicos | |
CL2020002423A1 (es) | Nuevos compuestos heterocíclicos | |
CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
CO2021002382A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
CO2022002336A2 (es) | Compuestos heterocíclicos | |
CL2022000556A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
CL2008002132A1 (es) | Compuestos derivados de sulfonamidas, moduladores de trpm8; composiciones farmaceuticas que comprenden a dichos compuestos; y uso de dichos compuestos en el tratamiento del dolor neuropatico, dolor inflamatorio, ansiedad, depresion, hiperalgesia inflamatoria, entre otras. | |
UY31093A1 (es) | Compuestos de ariloazol-2-il cianoetilamino, método para prepararlos y método para utilizarlos | |
ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
UY31750A (es) | Compuestos y composiciones como inhibidores de quinasa | |
CR20230115A (es) | Compuestos heterocíclicos | |
ECSP099394A (es) | Derivados de quinuclidinol como antogonistas de receptores muscarínicos | |
CR11220A (es) | Derivados de pirimidina 934 | |
CO2022002339A2 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
CO2023014721A2 (es) | Compuestos heterocíclicos | |
CO2022013856A2 (es) | Derivados de benzodiazepinas como pam de gaba a gamma1 | |
CO2022000186A2 (es) | Nuevos compuestos heterocíclicos | |
CO2023010212A2 (es) | Derivados novedosos de pirimidin-2-il sulfonamida | |
CO2018011231A2 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad por los receptores canabinoides tipo-2 | |
UY29485A1 (es) | Esteres alquílicos de aminoalcoholes cíclicos, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
DOP2021000063A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CL2020002058A1 (es) | Piridincarboxamidas novedosas. |